自体移植前基于PD-1的组合与经典霍奇金淋巴瘤的改善结果有关
Sanjal H Desai1, Alison J Moskowitz2, Reid W Merryman3
1University of Minnesota, Minneapolis, Minnesota, United States.
Blood
|December 17, 2025
概括
自主干细胞移植 (ASCT) 之前的抗PD-1疗法显著改善了复发/耐药古典霍奇金淋巴瘤 (cHL) 患者的治疗结果. 基于PD-1封锁的救援方案可以提高ASCT后的无进展生存率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学恶性瘤是什么
背景情况:
- 结合PD-1阻断的联合疗法在经典霍奇金淋巴瘤 (cHL) 中显示出高响应率.
- 以前的研究表明PD-1阻塞在ASCT前有好处,但对并发化疗使用的数据有限.
- 在ASCT之前,复发性/耐火性 (R/R) cHL需要有效的救援策略.
研究的目的:
- 评估基于抗PD-1的救援疗法对接受ASCT的R/RcHL患者的结果的影响.
- 为了比较在R/R cHL中ASCT之前的不同救援方案之间的结果.
主要方法:
- 在2010-2022年期间接受ASCT的1280名R/RcHL患者的回顾性审查.
- 在ASCT之前,对接受PD-1抑制剂 (有或没有化疗),单独使用布伦图西马布维多丁 (BV) 或单独使用化疗的患者进行分析.
- 在治疗组中比较两年无进展生存期 (PFS).
主要成果:
- 在ASCT前接受PD-1抑制剂的患者在2年后的PFS (88.2%) 与单独BV (70.2%) 或单独化疗 (67.4%) 相比显著更高 (p < 0.0001).
- 这种益处甚至在分析ASCT前完全响应 (CR) 的患者时也存在.
- 在ASCT之前使用PD-1阻塞独立地与ASCT后的优异结果有关.
结论:
- 基于PD-1阻塞的救援疗法与接受ASCT的R/RcHL患者的优异结果有关.
- 进行ASCT的R/RcHL患者应考虑基于PD-1的救援方案.
- 集成到救援方案中的抗PD-1疗法代表了管理R/RcHL的关键进步.
更多相关视频
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.0K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.7K
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
01:22Bone Marrow Sampling and Transplants
816
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
816